Wockhardt incorporated in 1999, is engaged the pharmaceutical and biotechnology segments. The company’s 14 manufacturing plants are located in India, UK, Ireland, US, and are compliant to international regulatory standards including US FDA and UK MHRA. These manufacturing plants are multi-technology and can manufacture all the dosage forms including sterile products as well as products with lyophilised dosage forms.
The company has 4 research centres globally with over 550 scientists of which over 100 are doctorates. Its multi-disciplinary research activities encompass pharmaceutical formulations, biopharmaceutical bulk and formulations, novel drug delivery system, new drug discovery programme and process engineering for Active Pharmaceutical Ingredients.
Wockhardt’s subsidiaries are located in the US, UK, Ireland and France. The company has market presence in formulations, bio-pharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs).
The company holds strong position in leading markets such as Europe and United States, which contributes 65% to Wockhardt's revenue. The company has two subsidiaries Negma Lerads, France and Morton Grove Pharmaceuticals, USA.
Wockhardt is the 4th company in the world to have developed recombinant insulin, Wosulin - from concept to market stage. It also developed a patented delivery device ‘Pen’ for Wosulin injections.
Wockhardt’s core business is innovation. It uses science and technology to develop medicines and other products that improve the quality of millions people’s lives through better health.
Biopharmaceutical- Under this the company has developed a basket of products such as Erythropoietin, Recombinant Human Insulin, Glargine are among others. The company sells 23 products under generic segment in US market.
Wockhardt has set up Wockhardt Biotech Park a biopharmaceuticals manufacturing complex located at Aurangabad, India. This complex comprises six manufacturing facilities developed as per USFDA and EMEA standards. It has capacity to serve 10-15% of global demand for major biopharmaceuticals.
In new drug discovery area, it has developed number of lead molecules in the anti-infective field.
Currently the company has a significant presence in pain management, cough therapy, psychotic drugs, diabetology, vaccines, nutrition and animal health.
It has produced brands like Wosulin, Wepox, Proxyvon, Dexolac, Viscodyne, Libotryp, Methycobal and many more.
Wockhardt has vast international expertise in the manufacture of pharmaceuticals and biopharmaceutical formulations as well as Active Pharmaceutical Ingredients (API).
The company has successfully created an integrated multi-technology capability to manufacture all types of dosage forms including sterile injectables and lyophilised products. Highly skilled technicians operate 14 manufacturing facilities that are US FDA, UK MHRA and EMEA compliant sites in India, the US and Europe.
The state-of-the-art biotech plant in Aurangabad has six dedicated manufacturing facilities for biopharmaceutical bulk as well as recombinant formulations. The Wockhardt Biotech Park has created its own benchmark in manufacturing recombinant products with world-class technology.
Wockhardt has proved its technical excellence by developing patented modified release formulations and recombinant biotechnology products. It has a multi-disciplinary R&D programme with more than 550 scientists, including over 100 doctorates, in the areas of:
Wockhardt is in the forefront of Intellectual Property creation with 1,411 patents filed till date, of which 145 patents have been granted. Our capability and commitment in pursuing Intellectual Property has been recognized by the Government of India for three years in a row, with an award for the maximum number of ‘Patent filings and Grants from India’. Wockhardt is determined to create benchmarks for a promising future.
In July 2013 US FDA and UK MHRA conducted inspections at Chikalthana. UKMHRA has issued a restricted GMP certificate for the Chikalthana facility to allow manufacture of 10 critical products whilst withdrawing the GMP certification of the said facility. Further UKMHRA has also issued a Drug Alert for recall of certain (and not all) non-critical products that were manufactured at Chikalthana, however, it has reiterated that there is no evidence of risk to patient safety from the products being recalled.
In November 2013, US FDA has placed the facility under Import Alert. However, US FDA has excluded 5 products from the import alert.
-Wockhardt receives US FDA approval for antibacterial Levofloxacin-Wockhardt launches Prostate drug Flomax in the United States on Day-1.-Wockhardt receives US FDA approval for the generic version of Toprol XL, a cardiac drug.
2011-Wockhardt launches generic version of Protonix tablets in the US.-Wockhardt receives US FDA approval for generic version of Effexor XR capsules.-Wockhardt launches three new products in three weeks, in the United States.-Wockhardt receives tentative US FDA approval for generic version of Patanol® ophthalmic solution.
-Wockhardt launches generic version of anti-ulcer drug Prevacid.-Wockhardt receives US FDA approval for generic version of Parkinsonism drug Requip XL.-Wockhardt receives tentative US FDA approval for generic version of anti-psychotic drug Geodon.-Wockhardt receives US FDA approval for generic version of Parkinson’s drug Comtan.
Wockhardt receives the 'Best Enterprise' award from the Europe Business Assembly
Wockhardt launches generic version of anti-convulsant drug Lamictal XR